223 related articles for article (PubMed ID: 2180469)
1. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndrome: a survey by the Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
De Witte T; Zwaan F; Hermans J; Vernant J; Kolb H; Vossen J; Lönnqvist B; Beelen D; Ferrant A; Gmür J
Br J Haematol; 1990 Feb; 74(2):151-5. PubMed ID: 2180469
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes. Leukaemia Working Party of the European Bone Marrow Transplantation Group (EBMTG).
De Witte T; Zwaan F; Hermans J; Vernant J; Kolb H; Vossen J; Lönnqvist B; Beelen D; Ferrant A; Gmür J
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():38-9. PubMed ID: 2697398
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow transplantation from HLA-identical siblings as first-line treatment in patients with myelodysplastic syndromes: early transplantation is associated with improved outcome. Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation.
Runde V; de Witte T; Arnold R; Gratwohl A; Hermans J; van Biezen A; Niederwieser D; Labopin M; Walter-Noel MP; Bacigalupo A; Jacobsen N; Ljungman P; Carreras E; Kolb HJ; Aul C; Apperley J
Bone Marrow Transplant; 1998 Feb; 21(3):255-61. PubMed ID: 9489648
[TBL] [Abstract][Full Text] [Related]
4. Intensively timed induction therapy followed by autologous or allogeneic bone marrow transplantation for children with acute myeloid leukemia or myelodysplastic syndrome: a Childrens Cancer Group pilot study.
Woods WG; Kobrinsky N; Buckley J; Neudorf S; Sanders J; Miller L; Barnard D; Benjamin D; DeSwarte J; Kalousek D
J Clin Oncol; 1993 Aug; 11(8):1448-57. PubMed ID: 8336184
[TBL] [Abstract][Full Text] [Related]
5. Treatment of patients with myelodysplastic syndromes with allogeneic bone marrow transplantation from genotypically HLA-identical sibling and alternative donors.
Demuynck H; Verhoef GE; Zachee P; Emonds MP; van der Schueren E; van den Berghe H; Vandenberghe P; Casteels-Van Daele M; Boogaerts MA
Bone Marrow Transplant; 1996 May; 17(5):745-51. PubMed ID: 8733692
[TBL] [Abstract][Full Text] [Related]
6. Unrelated bone marrow transplantation in patients with myelodysplastic syndromes and secondary acute myeloid leukemia: an EBMT survey. European Blood and Marrow Transplantation Group.
Arnold R; de Witte T; van Biezen A; Hermans J; Jacobsen N; Runde V; Gratwohl A; Apperley JF
Bone Marrow Transplant; 1998 Jun; 21(12):1213-6. PubMed ID: 9674854
[TBL] [Abstract][Full Text] [Related]
7. Intensive antileukemic treatment of patients younger than 65 years with myelodysplastic syndromes and secondary acute myelogenous leukemia.
De Witte T; Muus P; De Pauw B; Haanen C
Cancer; 1990 Sep; 66(5):831-7. PubMed ID: 2386911
[TBL] [Abstract][Full Text] [Related]
8. Intensive chemotherapy for patients with myelodysplastic syndromes and acute myelogenous leukaemia younger than 65 years.
De Witte T; Muus P; De Pauw B; Haanen C
Bone Marrow Transplant; 1989 Dec; 4 Suppl 3():33-5. PubMed ID: 2697396
[TBL] [Abstract][Full Text] [Related]
9. Prognostic variables in bone marrow transplantation for secondary leukaemia and myelodysplastic syndromes: a survey of the working party on leukaemia.
de Witte T; Hermans J; van Biezen A; Vernant J; Kolb H; Zwaan F; Vossen J; Lönnqvist B; Beelen D; Ferrant A
Bone Marrow Transplant; 1991; 7 Suppl 2():40. PubMed ID: 1878713
[No Abstract] [Full Text] [Related]
10. Intensive chemotherapy for poor prognosis myelodysplasia (MDS) and secondary acute myeloid leukemia (sAML) following MDS of more than 6 months duration. A pilot study by the Leukemia Cooperative Group of the European Organisation for Research and Treatment in Cancer (EORTC-LCG).
de Witte T; Suciu S; Peetermans M; Fenaux P; Strijckmans P; Hayat M; Jaksic B; Selleslag D; Zittoun R; Dardenne M
Leukemia; 1995 Nov; 9(11):1805-11. PubMed ID: 7475266
[TBL] [Abstract][Full Text] [Related]
11. Prospective study of 90 children requiring treatment for juvenile myelomonocytic leukemia or myelodysplastic syndrome: a report from the Children's Cancer Group.
Woods WG; Barnard DR; Alonzo TA; Buckley JD; Kobrinsky N; Arthur DC; Sanders J; Neudorf S; Gold S; Lange BJ
J Clin Oncol; 2002 Jan; 20(2):434-40. PubMed ID: 11786571
[TBL] [Abstract][Full Text] [Related]
12. Relapse after allogeneic bone marrow transplantation for acute leukaemia: a survey by the E.B.M.T. of 117 cases.
Frassoni F; Barrett AJ; Grañena A; Ernst P; Garthon G; Kolb HJ; Prentice HG; Vernant JP; Zwaan FE; Gratwohl A
Br J Haematol; 1988 Nov; 70(3):317-20. PubMed ID: 3061443
[TBL] [Abstract][Full Text] [Related]
13. Busulfan, cyclophosphamide and melphalan as conditioning regimen for bone marrow transplantation in children with myelodysplastic syndromes.
Locatelli F; Pession A; Bonetti F; Maserati E; Prete L; Pedrazzoli P; Zecca M; Prete A; Paolucci P; Cazzola M
Leukemia; 1994 May; 8(5):844-9. PubMed ID: 8182940
[TBL] [Abstract][Full Text] [Related]
14. Allogeneic bone marrow transplantation for secondary leukemia or myelodysplasia.
Witherspoon RP; Deeg HJ
Haematologica; 1999 Dec; 84(12):1085-7. PubMed ID: 10586209
[TBL] [Abstract][Full Text] [Related]
15. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-intensity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia.
Kröger N; Bornhäuser M; Ehninger G; Schwerdtfeger R; Biersack H; Sayer HG; Wandt H; Schäfer-Eckardt K; Beyer J; Kiehl M; Zander AR;
Ann Hematol; 2003 Jun; 82(6):336-42. PubMed ID: 12728337
[TBL] [Abstract][Full Text] [Related]
16. Bone marrow transplantation for myelodysplasia and secondary acute nonlymphoblastic leukemia.
Longmore G; Guinan EC; Weinstein HJ; Gelber RD; Rappeport JM; Antin JH
J Clin Oncol; 1990 Oct; 8(10):1707-14. PubMed ID: 2213106
[TBL] [Abstract][Full Text] [Related]
17. Prognostic factors in adult de novo myelodysplastic syndromes treated by intensive chemotherapy.
Fenaux P; Morel P; Rose C; Lai JL; Jouet JP; Bauters F
Br J Haematol; 1991 Apr; 77(4):497-501. PubMed ID: 2025575
[TBL] [Abstract][Full Text] [Related]
18. Are patients with acute leukaemia, alive and well 2 years post bone marrow transplantation cured? A European survey. Acute Leukaemia Working Party of the European Group for Bone Marrow Transplantation (EBMT).
Frassoni F; Labopin M; Gluckman E; Prentice HG; Gahrton G; Mandelli F; Carella M; Herve P; Gratwohl A; Goldman J
Leukemia; 1994 Jun; 8(6):924-8. PubMed ID: 8207985
[TBL] [Abstract][Full Text] [Related]
19. Randomised comparison of addition of autologous bone-marrow transplantation to intensive chemotherapy for acute myeloid leukaemia in first remission: results of MRC AML 10 trial. UK Medical Research Council Adult and Children's Leukaemia Working Parties.
Burnett AK; Goldstone AH; Stevens RM; Hann IM; Rees JK; Gray RG; Wheatley K
Lancet; 1998 Mar; 351(9104):700-8. PubMed ID: 9504514
[TBL] [Abstract][Full Text] [Related]
20. Retrospective evaluation of autologous bone marrow transplantation vs allogeneic bone marrow transplantation from an HLA identical related donor in acute myelocytic leukemia. A study of the European Cooperative Group for Blood and Marrow Transplantation (EBMT).
Gorin NC; Labopin M; Fouillard L; Meloni G; Frassoni F; Iriondo A; Brunet Mauri S; Goldstone AH; Harousseau JL; Reiffers J; Esperou-Bourdeau H; Gluckman E
Bone Marrow Transplant; 1996 Jul; 18(1):111-7. PubMed ID: 8832003
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]